3Lavi R, Lavi S, Herman J,et al. Role of lipoprotein-associ-ated phospholipase A2 in atheroscle rosis [J]. Curr Ath-eroscler Rep,2008,21(10) : 230.
4Abuzeid AM, Hawe E, Humphries SE,et al. Associationbetween the Ala379Val variant of the lipoprotein associ-ated phospholipase A2 and risk of myocardial infarction inthe north and south of Europe[J]. Atherosclerosis?2003 ,35(168):283-288.
6Lavi S,Herman J,Lavi R. Role of lipoprotein-associated phospholipase A2 in atheroscle rosis[J].Current Atherosclerosis Report,2008,(10):230.
7Abuzeid AM,Hawe E,Humphries SE. Association between the Ala379Val variant to the lipoprotein-associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe[J].Atheroclerosis,2003,(168):283.
8Bhagat S,Gaiha M,Sharma VK. A comparative evaluation of C-reactive protein as a short-term prognostic marker in severe unstable angina-a preliminary study[J].Journal of the Association of Physicians of India,2003,(04):349-354.
9Turgut U,Huseyin S. Looking for our ten years results for coronary heart disease and ischecnic stroke group for the standpoint of haemostasis[J].Turk J Haematol,2002,(11):255-263.
10Li N,Li S,Yu C,et al.Plasma Lp-PLA2in acute coronary syndrome:association with major adverse cardiac events in a community-based cohort[J].Postgrad Med J,2010,122(4):200-205.
